SMS 2: Impact of Cancer Therapy on the Somatic Mutational Landscape of Normal Tissues (SMS2)

The Wellcome Sanger Institute

Status

Invitation-only

Conditions

Somatic Mutation

Cancer

Treatments

Other: sample collection

Other: Discussing study

Other: Seeking consent

Study type

Observational

Funder types

Other

Identifiers

NCT06832150

341204

Details and patient eligibility

About

Recently technology has been developed at the Wellcome Sanger Institute to allow clusters of cells with mutations to be detected in normal and diseased tissues. The researchers wish to determine how the number and nature of these mutant cell clusters change in response to treatments given to cancer patients (such as chemotherapy, radiotherapy, immunotherapy, and drugs targeted at specific mutations in tumours). As such the researchers wish to collect research samples of blood, cheek cells (via swabs) and urine from adult cancer patients receiving the above-mentioned treatments as part of their standard care. The researchers also wish to access any leftover tissue following surgery that is undertaken as part of these patient's treatment.

Full description

Disease and tissue aging are thought to be influenced by genetic changes, or mutations, acquired throughout life. These mutations provide clues regarding the genetic damage that occurred through the lifetime of the patient, and include mutations caused by environmental factors such as ultraviolet light from sunlight or tobacco smoke affecting the skin or internal tissues, respectively. Other mutations may occur due to errors in copying the genome as cells divide. Once a cell has acquired a mutation, the cell's daughters may inherit it. Eventually clusters of cells carrying the same mutation may form within tissues. If the mutations alter cell behaviour this may impact how cells behave and influence how a whole tissue functions.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or Female
Due to commence systemic treatment for histologically confirmed cancer at a - participating site
Age over 18 years
Able to give informed consent.
Able to give urine, blood and cheek swab samples on two occasions.
Likely to complete 3 months of treatment

Exclusion criteria

Anyone outside of the inclusion criteria plus individuals who Lack the capacity to provide informed consent and those who do not have a good command of the English language.
Any participant who is known to have Hep B, Hep C or HIV